For hidradenocarcinoma, apocrine carcinoma, and signet-ring call/histiocytoid carcinoma, HER2 inhibitors or selective estrogen receptor modulators may be administered [53,54,55,56,57,58]. Here, ESR1 is linked to hidradenocarcinoma.